Seniors For America

Looking After The Future

Health and Fitness Blog,, Offers Fresh and C

San Francisco, CA – Health and fitness blog,, has been designed to offer the most well-researched information tailored towards delivering the best quality of life to its visitors.
The spokesperson for the fitness, health, and wellness blog,, while describing their mission said, “The Potent Health is a Health and Fitness Blog, offering fresh and credible content on Healthy Living, Weight Loss, Keto Diet, Home Remedies & Fitness. With the numerous contributions of our health and fitness team, we strive to produce reliable and credible content for our users. We, at The Potent Health, have taken it upon ourselves to find answers to some of the most common health questions and health advice given by professionals.”
Taking into consideration that there are several health & fitness blogs offering information online that can be confusing and misleading, their team at aim to deliver to their blog visitors, a well-researched content which promotes healthy living.
As part of their well-tailored content for visitors, the health & fitness blog offers information on the keto diet, for visitors who wish to lose weight the right way while relying less on medications. As part of the content offered via their website, their blog offers in-depth and well-researched information regarding home remedies & fitness needs to help visitors maintain perfect health.
Some of the information offered via their blog site includes a selection of the Best Low-Carb Fruits for Keto Diets, which analyzes some of the tested and trusted fruits guaranteed to help weight loss enthusiasts better meet their goals while offering them the high-carb content they need to meet their goals.
Offered via their blog site are home remedies such as Toothache Relief: Powerful Home Remedies for Toothaches, Easy to Make Keto Snacks for beginners, Yoga for Migraines: Yoga Poses To Cure Migraines and Headaches, Gym Workouts: Effective Gym workout routines for beginners and more.
Their blog site is easy to navigate and has a user-friendly interface that has been customized for the best user experience. The blog visitors can enjoy well-arranged content, as they can choose from the available categories including Diet, Fitness, Healthy Living and Keto Diet, to access information particular to each subject of interest.
Visit for the best health and fitness information towards healthy living. Their company is headquartered at 548 Market St, San Francisco, CA 94104. For inquiries, contact their team via phone at (323) 763-6694 or via email at Visit their blog site for additional information regarding health & fitness.
Contact Person: Henry David
Email: Send Email
Phone: (323) 763-6694
Address: 548 Market St
City: San Francisco
State: California
Country: United States

Read More…

Given to YouTube by Independent Digital

Frustration Relief Music 811 · Serenity Music Relaxation

Zen Meditation Music 111: Relaxing Flute Piano Songs with Sounds of Nature for Yoga Relaxation Meditation Sleep Well & Anxiety Stress Free

℗ 2016 Rehegoo

Launched on: 2016-05-23

Auto-generated by YouTube.

DOctorJay said: Sphenopalatine ganglion block for relieving postdural puncture headache: technique and mechanism of action of block with a narrative review of efficacy
Topical Sphenopalatine Ganglion Block Compared With Epidural Blood Patch for Postdural Puncture Headache Management in Postpartum Patients: A Retro… – PubMed – NCBI
Sphenopalatine ganglion block for treatment of post-dural puncture headache in obstetric patients: An observational study Click to expand… You beat me to it. Yeah, some pretty solid evidence lately. Anecdotally, I’ve done it 3 times for PDPH with excellent relief and about a dozen or so for migraine. The great thing is the relief is instant.

Read More…

Please check out to find out more regarding our technique as well as to find out how you can have much less pain, relocation easier, and really feel fantastic!

This video clip is an excellent self massage, self myofascial launch and also workout series for any person who experiences frustrations, neck pain, stress or migraines. This is functions if you have a “slipped disc” or herniated disc or “crick” in your neck.
Also inspect out my article “How to Relieve Neck Pain In 5 Easy Steps”

I suffered through a period of years of chronic migraines. I called them minor migraines from caparison to others who described what they went through. Sure, I had my bouts of ‘curl in a ball and hope to die’ and the ‘turn those -= insert appropriate expletives here =- lights off episodes, still, I didn’t equate them as anywhere near as bad as what others described. That said .. they stopped as soon as I started HRT. Now I can honestly say that all I have are chronic headaches (physical issues) and it is quite a relief.

Read More…

PAIN RELIEF: Soothing Headache, Anxiety, stress and migraine headache Relief Healing Guided Meditation|Hypnotherapy// Are searching for alleviation without getting to into the medicine closet? Then this video is crafted specifically for you!

This directed recovery meditation … is a power healing journey in which I take you with a deep leisure procedure where you’ll be accepted by magnificent love, after that I take you via a gorgeous field where you will certainly be brought about uncover a beautiful natural healing health club developed especially for you to allow go of any discomfort, anxiousness as well as anxiety that you lug within your body … the whole led journey has been infused with high-frequency light energy to strongly magnify its healing for you Healing … anticipate legendary adjustments!
Subscribe ➡
☑ Love Me Back|Contributions are Greatly Appreciated thanks! ➡
☑ Download the MP3 of this Meditation with NO Intro ➡
☑ Take Your Healing to the Next Level and also Get the Healing Bundle Upgrade ➡ Check Back!

☑ Book a Personal Healing Session ➡
☑ Spiritual Tools: Books, Manifesting, Healing, Essential Oils + More ➡
☑ Links to Hook You Up ➡
► ► ► To dive right in and bypass the intro skip ahead to 0:00 … you’re welcome!
0:00 – 2:29 Minutes: Introduction.
2:29 – 43:47 Minutes: Healing Guided Journey.
43:47 – 45:03 Minutes: Journal Music
☑ Best Essential Oil Diffusers ➡
☑ Best Super Affordable 100% Pure Essential Oils ➡
☑ Best, Easy to Read as well as Apply Manifesting Books ➡
☑ Top Tools for Removing Negative Energy ➡
☑ Oracle Cards|Tarot card Cards|Angel Cards ➡
☑ MY HEALING BOUTIQUE ➡ … choose a solution that resonates deep within your heart and aligns with your soul
Infinity Light Healing.
FOCUS: Lisa Whatley.
Mount Elgin, Ontario.
Songs: ♫
” Dream Culture” “Dewdrop Fantasy” “Fluidscape” Kevin MacLeod (
Accredited under Creative Commons: By Attribution 3.0 License.

#GuidedMeditation #Meditation #Hypnosis.

SUMATRIPTAN SUCCINATE Tablet, Film Coated [Lake Erie Medical DBA Quality Care Products LLC]

(N = 46) (N = 46)
The estimated probability of achieving an initial headache response over the 4 hours following treatment is depicted in Figure 1.
Figure 1. Estimated Probability of Achieving Initial Headache Response Within 240 Minutes*
*The figure shows the probability over time of obtaining headache response (no or mild pain) following treatment with sumatriptan. The averages displayed are based on pooled data from the 3 clinical controlled trials providing evidence of efficacy. Kaplan-Meier plot with patients not achieving response and/or taking rescue within 240 minutes censored to 240 minutes.
For patients with migraine-associated nausea, photophobia, and/or phonophobia at baseline, there was a lower incidence of these symptoms at 2 hours (Study 1) and at 4 hours (Studies 1, 2, and 3) following administration of sumatriptan succinate tablets compared to placebo.
As early as 2 hours in Studies 2 and 3 or 4 hours in Study 1, through 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for pain relief in the form of a second dose of study treatment or other medication. The estimated probability of patients taking a second dose or other medication for migraine over the 24 hours following the initial dose of study treatment is summarized in Figure 2.
Figure 2. The Estimated Probability of Patients Taking a Second Dose or Other Medication for Migraine Over the 24 Hours Following the Initial Dose of Study Treatment*
*Kaplan-Meier plot based on data obtained in the 3 clinical controlled trials providing evidence of efficacy with patients not using additional treatments censored to 24 hours. Plot also includes patients who had no response to the initial dose. No remedication was allowed within 2 hours postdose.
There is evidence that doses above 50 mg do not provide a greater effect than 50 mg. There was no evidence to suggest that treatment with sumatriptan was associated with an increase in the severity of recurrent headaches. The efficacy of sumatriptan succinate tablets was unaffected by presence of aura; duration of headache prior to treatment; gender, age, or weight of the patient; relationship to menses; or concomitant use of common migraine prophylactic drugs (e.g., beta- blockers, calcium channel blockers, tricyclic antidepressants). There were insufficient data to assess the impact of race on efficacy. INDICATIONS AND USAGE Sumatriptan succinate tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.
Sumatriptan succinate tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan succinate tablets have not been established for cluster headache, which is present in an older, predominantly male population. CONTRAINDICATIONS Sumatriptan succinate tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate tablets. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease (see WARNINGS ).
Because sumatriptan succinate tablets may increase blood pressure, they should not be given to patients with uncontrolled hypertension.
Concurrent administration of MAO-A inhibitors or use within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated (see CLINICAL PHARMACOLOGY: Drug Interactions and PRECAUTIONS: Drug Interactions ).
Sumatriptan succinate tablets should not be administered to patients with hemiplegic or basilar migraine.
Sumatriptan succinate tablets and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should sumatriptan succinate and another 5- HT 1 agonist.
Sumatriptan succinate tablets are contraindicated in patients with hypersensitivity to sumatriptan or any of their components.
Sumatriptan succinate tablets are contraindicated in patients with severe hepatic impairment. WARNINGS Sumatriptan succinate tablets should only be used where a clear diagnosis of migraine headache has been established.
Risk of Myocardial Ischemia and/or Infarction and Other Adverse Cardiac Events: Sumatriptan should not be given to patients with documented ischemic or vasospastic coronary artery disease (CAD) (see CONTRAINDICATIONS ). It is strongly recommended that sumatriptan not be given to patients in whom unrecognized CAD is predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery vasospasm is modest, at best. If, during the cardiovascular evaluation, the patient’s medical history or electrocardiographic investigations reveal findings indicative of, or consistent with, coronary artery vasospasm or myocardial ischemia, sumatriptan should not be administered (see CONTRAINDICATIONS ).
For patients with risk factors predictive of CAD, who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of sumatriptan tablets take place in the setting of a physician’s office or similar medically staffed and equipped facility unless the patient has previously received sumatriptan. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following sumatriptan succinate tablets, in these patients with risk factors.
It is recommended that patients who are intermittent long-term users of sumatriptan and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use sumatriptan.
The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to sumatriptan.
Drug-Associated Cardiac Events and Fatalities: Serious adverse cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours following the administration of sumatriptan succinate injection or sumatriptan succinate tablets. Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low.
The fact that sumatriptan can cause coronary vasospasm, that some of these events have occurred in patients with no prior cardiac disease history and with documented absence of CAD, and the close proximity of the events to sumatriptan use support the conclusion that some of these cases were caused by the drug. In many cases, however, where there has been known underlying coronary artery disease, the relationship is uncertain.
Premarketing Experience With Sumatriptan : Of 6,348 patients with migraine who participated in premarketing controlled and uncontrolled clinical trials of oral sumatriptan, 2 experienced clinical adverse events shortly after receiving oral sumatriptan that may have reflected coronary vasospasm. Neither of these adverse events was associated with a serious clinical outcome.
Among the more than 1,900 patients with migraine who participated in premarketing controlled clinical trials of subcutaneous sumatriptan, there were 8 patients who sustained clinical events during or shortly after receiving sumatriptan that may have reflected coronary artery vasospasm. Six of these 8 patients had ECG changes consistent with transient ischemia, but without accompanying clinical symptoms or signs. Of these 8 patients, 4 had either findings suggestive of CAD or risk factors predictive of CAD prior to study enrollment.
Among approximately 4,000 patients with migraine who participated in premarketing controlled and uncontrolled clinical trials of sumatriptan nasal spray, 1 patient experienced an asymptomatic subendocardial infarction possibly subsequent to a coronary vasospastic event.
Postmarketing Experience With Sumatriptan : Serious cardiovascular events, some resulting in death, have been reported in association with the use of sumatriptan succinate injection or sumatriptan succinate tablets. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to determine definitively the proportion of the reported cases that were actually caused by sumatriptan or to reliably assess causation in individual cases. On clinical grounds, the longer the latency between the administration of sumatriptan succinate and the onset of the clinical event, the less likely the association is to be causative. Accordingly, interest has focused on events beginning within 1 hour of the administration of sumatriptan succinate.
Cardiac events that have been observed to have onset within 1 hour of sumatriptan administration include: coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation, cardiac arrest, and death.
Some of these events occurred in patients who had no findings of CAD and appear to represent consequences of coronary artery vasospasm. However, among domestic reports of serious cardiac events within 1 hour of sumatriptan administration, almost all of the patients had risk factors predictive of CAD and the presence of significant underlying CAD was established in most cases (see CONTRAINDICATIONS ).
Drug-Associated Cerebrovascular Events and Fatalities: Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with oral or subcutaneous sumatriptan, and some have resulted in fatalities. The relationship of sumatriptan to these events is uncertain. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine when they were not. As with other acute migraine therapies, before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. It should also be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., cerebro-vascular accident, transient ischemic attack).
Other Vasospasm-Related Events : Sumatriptan may cause vasospastic reactions other than coronary artery vasospasm. Both peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea have been reported.
Serotonin Syndrome: The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with sumatriptan succinate, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).
Increase in Blood Pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients with and without a history of hypertension. Sumatriptan is contraindicated in patients with uncontrolled hypertension (see CONTRAINDICATIONS ). Sumatriptan should be administered with caution to patients with controlled hypertension as transient increases in blood pressure and peripheral vascular resistance have been observed in a small proportion of patients.
Concomitant Drug Use : In patients taking MAO-A inhibitors, sumatriptan plasma levels attained after treatment with recommended doses are 7-fold higher following oral administration than those obtained under other conditions. Accordingly, the coadministration of sumatriptan succinate tablets and an MAO-A inhibitor is contraindicated (see CLINICAL PHARMACOLOGY and CONTRAINDICATIONS ).
Hypersensitivity: Hypersensitivity (anaphylaxis/anaphylactoid) reactions have occurred on rare occasions in patients receiving sumatriptan. Such reactions can be life threatening or fatal. In general, hypersensitivity reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens (see CONTRAINDICATIONS ). PRECAUTIONS General Chest discomfort and jaw or neck tightness have been reported following use of sumatriptan succinate tablets and have also been reported infrequently following administration of sumatriptan succinate nasal spray. Chest, jaw, or neck tightness is relatively common after administration of sumatriptan succinate injection. Only rarely have these symptoms been associated with ischemic ECG changes. However, because sumatriptan may cause coronary artery vasospasm, patients who experience signs or symptoms suggestive of angina following sumatriptan should be evaluated for the presence of CAD or a predisposition to Prinzmetal variant angina before receiving additional doses of sumatriptan, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud syndrome following sumatriptan should be evaluated for atherosclerosis or predisposition to vasospasm (see WARNINGS ).
Sumatriptan succinate tablets should also be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs, such as impaired hepatic or renal function.
There have been rare reports of seizure following administration of sumatriptan. Sumatriptan should be used with caution in patients with a history of epilepsy or conditions associated with a lowered seizure threshold.
Care should be taken to exclude other potentially serious neurologic conditions before treating headache in patients not previously diagnosed with migraine headache or who experience a headache that is atypical for them. There have been rare reports where patients received sumatriptan for severe headaches that were subsequently shown to have been secondary to an evolving neurologic lesion (see WARNINGS ).
For a given attack, if a patient does not respond to the first dose of sumatriptan, the diagnosis of migraine should be reconsidered before administration of a second dose.
Overuse of acute migraine treatments has been associated with the exacerbation of headache (medication overuse headache) in susceptible patients. Withdrawal of the treatment may be necessary.
Binding to Melanin-Containing Tissues : In rats treated with a single subcutaneous dose (0.5 mg/kg) or oral dose (2 mg/kg) of radiolabeled sumatriptan, the elimination half-life of radioactivity from the eye was 15 and 23 days, respectively, suggesting that sumatriptan and/or its metabolites bind to the melanin of the eye. Because there could be an accumulation in melanin-rich tissues over time, this raises the possibility that sumatriptan could cause toxicity in these tissues after extended use. However, no effects on the retina related to treatment with sumatriptan were noted in any of the oral or subcutaneous toxicity studies. Although no systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long-term ophthalmologic effects.
Corneal Opacities : Sumatriptan causes corneal opacities and defects in the corneal epithelium in dogs; this raises the possibility that these changes may occur in humans. While patients were not systematically evaluated for these changes in clinical trials, and no specific recommendations for monitoring are being offered, prescribers should be aware of the possibility of these changes (see ANIMAL TOXICOLOGY ). Information for Patients See PATIENT INFORMATION at the end of this labeling for the text of the separate leaflet provided for patients.
Patients should be cautioned about the risk of serotonin syndrome with the use of sumatriptan or other triptans, especially during combined use with SSRIs or SNRIs. Laboratory Tests No specific laboratory tests are recommended for monitoring patients prior to and/or after treatment with sumatriptan. Drug Interactions Selective Serotonin Reuptake Inhibitors/Serotonin
Norepinephrine Reuptake Inhibitors and Serotonin Syndrome: Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs or SNRIs and triptans (see WARNINGS ).
Ergot-Containing Drugs: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided (see CONTRAINDICATIONS ).
Monoamine Oxidase-A Inhibitors: MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated (see CLINICAL PHARMACOLOGY and CONTRAINDICATIONS ). Drug/Laboratory Test Interactions Sumatriptan succinate tablets are not known to interfere with commonly employed clinical laboratory tests. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis: In carcinogenicity studies, rats and mice were given sumatriptan by oral gavage (rats, 104 weeks) or drinking water (mice, 78 weeks). Average exposures achieved in mice receiving the highest dose (target dose of 160 mg/kg/day) were approximately 40 times the exposure attained in humans after the maximum recommended single oral dose of 100 mg. The highest dose administered to rats (160 mg/kg/day, reduced from 360 mg/kg/day during week 21) was approximately 15 times the maximum recommended single human oral dose of 100 mg on a mg/m 2 basis. There was no evidence of an increase in tumors in either species related to sumatriptan administration.
Mutagenesis : Sumatriptan was not mutagenic in the presence or absence of metabolic activation when tested in 2 gene mutation assays (the Ames test and the in vitro mammalian Chinese hamster V79/HGPRT assay). In 2 cytogenetics assays (the in vitro human lymphocyte assay and the in vivo rat micronucleus assay) sumatriptan was not associated with clastogenic activity.
Impairment of Fertility : In a study in which male and female rats were dosed daily with oral sumatriptan prior to and throughout the mating period, there was a treatment-related decrease in fertility secondary to a decrease in mating in animals treated with 50 and 500 mg/kg/day. The highest no-effect dose for this finding was 5 mg/kg/day, or approximately one half of the maximum recommended single human oral dose of 100 mg on a mg/m 2 basis. It is not clear whether the problem is associated with treatment of the males or females or both combined. In a similar study by the subcutaneous route there was no evidence of impaired fertility at 60 mg/kg/day, the maximum dose tested, which is equivalent to approximately 6 times the maximum recommended single human oral dose of 100 mg on a mg/m 2 basis. Pregnancy Teratogenic Effects Pregnancy Category C : In reproductive toxicity studies in rats and rabbits, oral treatment with sumatriptan was associated with embryolethality, fetal abnormalities, and pup mortality. When administered by the intravenous route to rabbits, sumatriptan has been shown to be embryolethal. There are no adequate and well-controlled studies in pregnant women. Therefore, sumatriptan succinate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In assessing this information, the following findings should be considered. Embryolethality When given orally or intravenously to pregnant rabbits daily throughout the period of organogenesis, sumatriptan caused embryolethality at doses at or close to those producing maternal toxicity. In the oral studies this dose was 100 mg/kg/day, and in the intravenous studies this dose was 2 mg/kg/day. The mechanism of the embryolethality is not known. The highest no-effect dose for embryolethality by the oral route was 50 mg/kg/day, which is approximately 9 times the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis. By the intravenous route, the highest no-effect dose was 0.75 mg/kg/day, or approximately one tenth of the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis.
The intravenous administration of sumatriptan to pregnant rats throughout organogenesis at 12.5 mg/kg/day, the maximum dose tested, did not cause embryolethality. This dose is equivalent to the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis. Additionally, in a study in rats given subcutaneous sumatriptan daily prior to and throughout pregnancy at 60 mg/kg/day, the maximum dose tested, there was no evidence of increased embryo/fetal lethality. This dose is equivalent to approximately 6 times the maximum recommended single human oral dose of 100 mg on a mg/m 2 basis. Teratogenicity Oral treatment of pregnant rats with sumatriptan during the period of organogenesis resulted in an increased incidence of blood vessel abnormalities (cervicothoracic and umbilical) at doses of approximately 250 mg/kg/day or higher. The highest no-effect dose was approximately 60 mg/kg/day, which is approximately 6 times the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis. Oral treatment of pregnant rabbits with sumatriptan during the period of organogenesis resulted in an increased incidence of cervicothoracic vascular and skeletal abnormalities. The highest no-effect dose for these effects was 15 mg/kg/day, or approximately 3 times the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis.
A study in which rats were dosed daily with oral sumatriptan prior to and throughout gestation demonstrated embryo/fetal toxicity (decreased body weight, decreased ossification, increased incidence of rib variations) and an increased incidence of a syndrome of malformations (short tail/short body and vertebral disorganization) at 500 mg/kg/day. The highest no-effect dose was 50 mg/kg/day, or approximately 5 times the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis. In a study in rats dosed daily with subcutaneous sumatriptan prior to and throughout pregnancy, at a dose of 60 mg/kg/day, the maximum dose tested, there was no evidence of teratogenicity. This dose is equivalent to approximately 6 times the maximum recommended single human oral dose of 100 mg on a mg/m 2 basis. Pup Deaths Oral treatment of pregnant rats with sumatriptan during the period of organogenesis resulted in a decrease in pup survival between birth and postnatal day 4 at doses of approximately 250 mg/kg/day or higher. The highest no-effect dose for this effect was approximately 60 mg/kg/day, or 6 times the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis.
Oral treatment of pregnant rats with sumatriptan from gestational day 17 through postnatal day 21 demonstrated a decrease in pup survival measured at postnatal days 2, 4, and 20 at the dose of 1,000 mg/kg/day. The highest no-effect dose for this finding was 100 mg/kg/day, approximately 10 times the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis. In a similar study in rats by the subcutaneous route there was no increase in pup death at 81 mg/kg/day, the highest dose tested, which is equivalent to 8 times the maximum single recommended human oral dose of 100 mg on a mg/m 2 basis. Nursing Mothers Sumatriptan is excreted in human breast milk following subcutaneous administration. Infant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hours after treatment with sumatriptan succinate tablets. Pediatric Use Safety and effectiveness of sumatriptan succinate tablets in pediatric patients have not been established.
Completed placebo-controlled clinical trials evaluating oral sumatriptan (25 to 100 mg) in pediatric patients aged 12 to 17 years enrolled a total of 701 adolescent migraineurs. These studies did not establish the efficacy of oral sumatriptan compared to placebo in the treatment of migraine in adolescents. Adverse events observed in these clinical trials were similar in nature to those reported in clinical trials in adults. The frequency of all adverse events in these patients appeared to be both dose- and age-dependent, with younger patients reporting events more commonly than older adolescents.
Postmarketing experience includes a limited number of reports that describe pediatric patients who have experienced adverse events, some clinically serious, after use of subcutaneous sumatriptan and/or oral sumatriptan. These reports include events similar in nature to those reported rarely in adults. A myocardial infarction has been reported in a 14-year-old male following the use of oral sumatriptan; clinical signs occurred within 1 day of drug administration. Since clinical data to determine the frequency of serious adverse events in pediatric patients who might receive injectable, oral, or intranasal sumatriptan are not presently available, the use of sumatriptan in patients aged younger than 18 years is not recommended. Geriatric Use The use of sumatriptan in elderly patients is not recommended because elderly patients are more likely to have decreased hepatic function, they are at higher risk for CAD, and blood pressure increases may be more pronounced in the elderly (see WARNINGS ). ADVERSE REACTIONS Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan succinate injection or tablets. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ).
Significant hypertensive episodes, including hypertensive crises, have been reported on rare occasions in patients with or without a history of hypertension (see WARNINGS ).
Incidence in Controlled Clinical Trials : Table 2 lists adverse events that occurred in placebo-controlled clinical trials in patients who took at least 1 dose of study drug. Only events that occurred at a frequency of 2% or more in any group treated with sumatriptan succinate tablets and were more frequent in that group than in the placebo group are included in Table 2. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ. Table 2. Treatment-Emergent Adverse Events Reported by at Least 2% of Patients in Controlled Migraine Trials* Adverse Event Type

Read More…

Hey Vortex fam,
Today we are going with some basic however powerful triggers. I’ll be carefully rubbing your head while whispering to your ears up close. This video is particularly made to get rid of your headache and also leave you with a kicked back state … I wish it’ll benefit you.
You merit.

This video is personalized for Michael who supports me on Patreon.

⭐ Support me on Patreon for Rewards:

⭐ Follow me on TINGLES for no advertisements:

Paypal Donation:

Vlog Channel:

Social media site:
instagram: vortexasmr
snapchat: xxroarxxroarxx

Look into Maggie’s network:

A HUGE Thank you to my Amazing Patrons:

Smooth Movements ASMR (Jayden).
Arlene O.
William T.
Emily W.
Tee Jay.
Anouk B.
Johnny P.
Elision ASMR.

Chronic Bronchitis – How To Treat And Avoid Bronchitis

signs and symptoms of bronchitis – How to Treat and Avoid Bronchitis How to Treat and Avoid Bronchitis Bronchitis is the inflammation of the bronchi of the lungs. It is a pulmonary disease from the COPD category. COPD means chronic obstructive pulmonary disease and the agents that may lead to this disease are viruses, bacteria, fungi or just breathing a polluted air, smoking or breathing the cigarettes smoke.Low temperatures in winter also influences the inflammation. Bronovil Natural Bronchitis Remedy Prevent virus from attacking your lungs Stop persistent cough Naturally relieve pain and fever Breathe easier – Metabolic disturbances (normalization of fatty acid and pH values) – Diabetes in the elderly – Incontinence, bed wetting with children – Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS),Treatment of Acute Bronchitis Acute bronchitis is the milder of the two types of bronchitis . There is no need to take any drugs to treat bronchitis of this type, which is a short-term disorder. Acute bronchitis lasts only for a couple of weeks or lesser if treated with care. The duration of the illness also depends on the type of microbe causing it.There are a lot of symptoms that are characteristic in Bronchitis . First of all there is a persistent, expectorating, dry or wet cough which is very frustrating for the patient, dyspnea or shortness of breath, fatigue, mild fever and mild chest pains.The breath sounds are also very important for the diagnosis. In Bronchitis apears the rhonchi which is the result of a decreased intensity of breath sounds and extended expiration.Before taking any sort of drug to treat bronchitis , consult your doctor. Your doctor will determine, on the basis of your medical history, whether or not a particular drug will be beneficial for you. Doctors are the most qualified to determine the best combination of drugs to treat bronchitis . They also give you the correct instruction about the usage of these drugs.Energy levels over 50% reflect health, vitality, less aging, high immune system activity. Energy levels under 50% reflect energy deficit, low immune system activity, disease condition, chronic diseases.Bronchitis is an inflammation of the bronchi (lung airways), resulting in persistent cough that produces consideration quantities of sputum (phlegm). Bronchitis is more common in smokers and in areas with high atmospheric pollution. Chronic bronchitis is a disease in which there is diffused inflammation of the air passages in the lungs, leading to decreased uptake of oxygen by the lungs and increased mucus production. Bronchitis usually occurs following a viral respiratory infection or with prolonged cigarette smoking.The first symptoms in Bronchitis are dry cough which turns into a wet one, fever, fatigue and headaches. All this may last for few days, maximum eleven days but the coughing lasts for weeks and even months. It is very important to mention that acute Bronchitis is very contagious. If the symptoms lasts for more than six months it is recommended that the doctor makes the necessary examination to find the cause of the persistent cough ing, because it can be asthma or TB. In TB it is characteristic the coughing accompanied by blood.- Virus infections, allergies, migraine and asthma – Tinnitus aurium (ear noises) and macular edema (retina damage) – Stress, sleep and digestive problemsThe new PRTH P5 professional treatment system is easy to use, non-invasive, pain free and highly effective for prevention and disease treatment. The energy increase can be monitored with the Meridian Diagnosis immediately after a treatment session.If the Bronchitis complicates it may cause pulmonary hypertension, chronic respiratory failure or even heart disease. It is not very hard to avoid acute Bronchitis . It is necessary just to wash your hands frequently, get more rest and drink plenty of liquids. Acute bronchitis is usually caused by viruses or bacteria. One can be contaminated with this agents by breathing coughing droplets from the air or by touching contaminated surfaces, by breathing polluted, by smoking or breathing cigarette smoke or other harmful smokes. It is recommended for the smokers in the early stages of chronic Bronchitis to quit smoking. This will help them to avoid complications and the treatment will give best results.Therapy suggestions are displayed with exact treatment points. One of the major advantages of the Meridian Diagnostic is the advantage to discover unknown Meridian Blockages in the system. When one or more meridian blockages exists the patient becomes Therapy Resistant, which means no therapy will have a sufficient effect. With the BioGraph meridian diagnostic system we are able not only to discover blockages furthermore we can treat and “delete” those blockages immediately. The patient turns from therapy resistant into therapy receptive. The therapy effects are re-established.However, some patients take expectorants to facilitate easier breathing. Anti-inflammatory drugs will help you obtain relief from the various symptoms of bronchitis . In certain cases, bronchitis can lead to very painful sinusitis. Decongestants will help you alleviate this symptom. You might also require pain killers to ease the muscle pain that always comes with bronchitis.DISEASES OF BONES, MUSCLES AND CONNECTIVE TISSUE: Infection, postinfection and reactive arthropathiae, rheumatoid arthritis, juvenile arthritis, gout, polyarthrosis, osteoarthritis deformans, articular cartilage lesions, ligaments lesions, joints luxations and subluxations, hemarthrosis, exudate in the joint, pain in the joint, rigidity of the joints, osteophytes (“spurs”), lupus erythematosus, dermatopolymyositis, systemic sclerosis (including sclerodermia), systemic vasculites, scoliosis, osteo-chondrosis, torticollis, ankylosing spondylitis, spondylopathiae, spondylosis, inter-vertebral disks lesions, radiculopathiae, radiculitis, ischias, lumbago, backaches, myosites (muscles inflammation), synovites, tenosynovitis and bursites, ligaments and joints injuries, pain in the limbs, other unspecified diseases of joints and soft tissues, bones fractures, poor fractures consolidation (including age-related fracture of the neck of the femur), osteomyelitis, periostitis, periodontitis, parodontosis, parodon-titis.CERTAIN CONDITIONS APPEARING IN PERINATAL PERIOD: Lesions of fetus and newborn caused by mother’s diseases and complications of pregnancy and childbirth, birth injuries, intrau-terine hypoxia, respiratory disorders of fetus and newborn, non-traumatic intracranial hemorrhage in fetus and newborn, neonatal jaundice, transitory neonatal endocrine disorders, digestive disorders in perinatal period, thermoregulation disorders and skin changes in fetus and newborn, regurgitation, vomiting, poor sucking and overfeeding, muscular tonus lesion in newborn.SKIN AND SUBCUTANEOUS FAT DISEASES: Skin abscess, furunculi and carbunculi, panaris, atopic dermatitis, seborrheic dermatitis, contact dermatitis, neurodermitis, psoriasis, Quincke’s edema, burns (including sunburns), frostbite, focal alopecia (baldness), follicular cysts of the skin and subcutaneous fat, hyperhidrosis (sweating), vitiligo, callosities, atrophic skin lesions (trophic ulcers), hypertrophic skin lesions (keloid cicatrices), erysipelas.You have to take antibiotics or antibacterial drugs to treat bronchitis that is caused by bacteria; the drugs destroy the bacteria that are infecting your bronchi. In rare cases, the bronchitis might be caused by a fungus, and you will have to take antifungal drugs in addition to the other medicines that tackle the symptoms of bronchitis .DIGESTIVE ORGANS DISEASES: Oral cavity diseases, pyrosis, esophagitis, gastroesophageal reflux, esophageal ulcer, esophageal dyskinesia, gastric ulcer, duodenal ulcer, acute and chronic gastritis and duodenitis of various origin, pylorospasm, Crohn’s disease, ulcerative colitis, acute and chronic gastroenteritis and colitis, irritated intestine syndrome with and without diarrhea, constipation, functional diarrhea, neu-rogenous excitability of the intestine, anal sphincter spasm, anal and rectal fissurae and fistulae, hemorrhoids, alcoholic liver disease, toxic liver lesion, acute and chronic hepatitis, hepatic fibro-sis and cirrhosis, cholelithiasis, acute and chronic cholecystitis, biliary tracts dyskinesia, acute and chronic pancreatitis, vomiting after surgical intervention on gastroenteric tract, postoperative intestinal obstruction (intestinal paresis), dysfunction after colosto-my and enterostomy, secondary disturbances of intestinal absorption, disturbance of alimentary behavior (overeating). Bronchitis , a respiratory disorder that can affect anybody at anytime, is one among the most widespread ailments. However, people residing in polluted areas, cigarette smokers, infants, young children, old people, and people already suffering from lung disorders are more susceptible to bronchitis .There are two kinds of Bronchitis. The acute or the short -term Bronchitis and the chronic or long -lasting one. There are different agents that determine the disease. Acute bronchitis is often the result of influenza, a cold or an infection. It may be caused by viruses or bacteria. Smoking, pneumoconiosis, excessive alcohol consumption and exposure to cold and draught are the most frequent agents that cause chronic Bronchitis . Chronic Bronchitis manifests with a persistent cough that produces sputum that lasts from three to six months during one or two years. Only in this circumstances we can speak about chronic Bronchitis . It also involves long lasting irritation caused by inhaling certain substances and especially tobacco smoke. This harmful substances determine the glands of the trachea and bronchi to increase the secretion of mucus. In this case the mucus can’t be evacuated anymore and it can determine the obstruction of the airways. It is also very possible that an acute Bronchitis becomes chronic.Acute bronchitis is usually due to an infection and generally lasts for no more than a few weeks and will resolve either with treatment or on its own. It can be caused by the same viruses that cause the common cold and is a common complication of the cold or flu.This reflects the most effective way to prevent any kind of disease long time before it would appear. In addition the treatment of existing diseases is not “blind” anymore and the patient – treatment response can be finalized through different therapy applicators. For example mat treatment for energy balancing and meridian harmonization, oxygen increase in the blood (65% after 10 minutes), immune system boost, better sleep and vitalization etc. The treatment with the head applicator for the central nervous system, head, eye, ear, nose diseases and brain related diseases like Parkinson, Multiple Sclerosis, Alzheimer’s etc. The intensive applicator for all joint related problems and to rebuild the cartilage, which is alone a phenomena and was completely impossible before. Finally a point applicator for any pain related circumstance. The PERTH therapy system is very easy to use, any therapist assistant can perform the treatment after a short introduction. As soon a therapy plan is in place patients for therapy or prevention can go in and out on their scheduled appointment without long waiting periods. Remedy ” i was so weak felt really tired and drained. i was coughing all the time had sore throats and really just felt disgusting. after 2 days on bronovil i felt much, much better. thanks ” Amanda from Tx Along with the medication and the rest of the treatment plan, it is essential that you stop smoking. The earlier you quit smoking, the sooner you can undo the damage done to your lungs.Treatment of Chronic Bronchitis On the other hand, chronic bronchitis , a long-term disorder, requires long-term care. If you are suffering from chronic bronchitis, you need to take a variety of drugs to obtain relief from the symptoms of the disorders along with drugs that might help cure the condition.Particular meridians and related organs are effected long time before a disease becomes a pathological issue. (green – normal, yellow – attention and red – signals treatment is necessary). For example most cancer patients have an energy level of only 25%, or energy deficit of 75%. This means the immune system is nearly not functioning anymore. Fertile ground for cancer cell grow is established without major defense. Cancer can spread in the body. The reverse circumstance high energy levels – a powerful immune system, health and vitality and a non toxic environment don’t allow cancer cell grow. Disease development of any kind becomes impossible. The Meridian Diagnosis and PERTH treatment combination will make those scenarios visible and immediate treatment plans can be developed. The treatment effect is tested and recorded on a patient by patient basis during the very first measurement – therapy – measurement sequence.- Climatic problems, potency problems – Rheumatic disease with chronic pains Indications are given in strict conformity with International Statistical Classification of Diseases and Health Problems of the 10th review, accepted by the 43rd World Health Assembly.For more resources on bronchitis or especially about bronchitis symptoms please click this link bronchitis -symptoms.htmChances for complete recovery from chronic bronchitis are slim. You need to identify the disease in its earliest stages and arrest its further progress immediately. You can do so by making major lifestyle changes such as moving to a cleaner area, quitting smoking, and giving up alcohol altogether.MENTAL AND BEHAVIORAL DISORDERS: Acute alcoholic intoxication, abstinent delirium (delirium tre-mens) and abstinent status without delirium, symptomatic treatment of chronic alcoholism, depressive disorders, neurotic, stress induced and somatoformic disorders (tic, vegetative nervous system disorders, enuresis, logoneurosis, etc.), sleep-awake regimen disturbances of inorganic etiology, absence or loss of sexual libido, insufficiency of sexual reaction (impotence of inorganic origin), orgasmic dysfunction, mental retardation.Indication: – Degenerative bone and joint disease (hip arthritis, Bechterew’s disease, Sudeck’s disease) – Arterial circulation disturbance (hardening of arteries in the leg as result of smoking, lower leg sores, stroke, heart attack)PREGNANCY, CHILDBIRTH AND POSTNATAL PERIOD: Arterial hypertension as complication of pregnancy, childbirth and postnatal period, edema and proteinuria caused by pregnancy, nephropathy of pregnancy, excessive vomiting of the pregnant, hemorrhoids, diabetes mellitus, herpes of the pregnant, arterial hypotony syndrome in mother, preparation for childbirth, anesthesia during childbirth, hypothermia of unclear origin appearing after childbirth, changes of mammary gland and lactation.Four (4) complete professional therapy systems on a therapy bed will serve app. 32-50 people treatments per day. The capacity can be extended to 8 therapy systems and will serve more than 64 people treatments per day. The basic research of the PERTH therapy started in the early 1920’s with Dr. Royal Rife (The end of all diseases), later research by over 200 Russian researcher for the space program MIR in Russia and since 1994 the research is finalized by a well known German researcher and medical professional Prof. Dr. Werner. In cooperation with leading German universities Werner developed the cancer and bone therapy programs with proven results in 1000’s of medical and clinical studies.NERVOUS SYSTEM DISEASES: The sequel of nervous system inflammatory diseases (meningitis, encephalitis, myelites, encephalomyelitis), Parkinson’s disease, multiple sclerosis, epilepsy, migraine, headache, transitory cerebral ischaemic attacks, sleeplessness, disturbances of sleep-awake cycles, trigeminal neuralgia, facial nerve lesions, neuralgia, neuritis, phantom limb pain syndrome, mononeuropathies, polyneuropathies (including diabetic), infantile cerebral paralysis, hemiplegia, paraplegia, tetraplegia and other paralytic syndromes, vegetative nervous system disorders, vascular (neurocirculatory) dystonia, hydrocephalus, toxic and other encephalopathies, intracranial hypertension (increase of intracranial pressure), fatigue syndrome in recovery period.- Stabilization of circulation – High and low blood pressure – Pulmonary emphysema – Osteoporosis – Radiant sickness – Acute and chronic nasal cavity sicknesses- Asthma, allergies, – Burnout syndrome – Cancer, Leukemia – Heart diseases – Liver cirrhoses – Eye diseases (cataract) – Venous circulation disturbance (thrombosis, thrombophlebitis)Modern society suffers mostly from various kinds of respiratory disorders, some contagious and some noncontagious. The markets are flooded with a variety of drugs to treat bronchitis and other disorders. All of us need to have adequate knowledge about how to maintain good health. We need to know the best drugs to treat bronchitis , in case we are stricken with it.There is no need to take any drugs to treat bronchitis that is caused by viruses. You simply need a lot of rest, water and fruit juices in abundance, and a humidifier. In addition, you have to avoid dust and polluted environments. The only drugs required in this conditions are those that alleviate the symptoms of bronchitis–anti-inflammatory drugs, pain killers, expectorants, and nasal decongestants.It is quite difficult to choose an appropriate treatment in chronic bronchitis . It is recommended to drink lots of liquids which are very helpful for the evacuation of the mucus. It was showed that antibiotics are not the right choice to treat Bronchitis , because the most of them are caused by viruses which don’t respond to this kind of treatment. The most appropriate medication is aspirin, an anti- fever drug and steroids to open bronchial tubes and ease coughing. It is also very important that the doctor prescribes anti -tusive drugs. This kind of drugs thin the mucus and they make coughing more effective. And they also helps patients to have a quiet sleep, this because the dry coughing that characterizes the early stages of bronchitis wakes them up and don’t let them sleep. So the best results are given by the oxygen therapy, bronchodilator drugs and if it is necessary lung volume reduction surgery.With Relieve Your Bronchitis Natural Remedy, you will start fighting bronchitis within minutes. You will learn the root germ that causes bronchitis, and how to keep it from returning. The coughing fits, the wheezing, and the aches and pains will stop. You will no longer have to miss, work and school due to illness. You can save a lot of money, from running to the doctors. You can say goodbye to harmful antibiotics or medication. TSigns And Symptoms ??? Fever is not common in people with acute bronchitis , although it may be a sign of another condition such as the flu or pneumonia. A persistent cough is the most common sign of acute bronchitis ; this usually lasts between 10 and 20 days. In some people, coughing produces sputum (mucus); this does not mean that there is a bacterial infection or that antibiotics are needed.ENDOCRINE SYSTEM DISEASES, NUTRITIVE AND METABOLIC DISORDERS: Hypothyrosis, clinical manifestations of hyperthyrosis (thyro-toxicosis), diabetes mellitus, adrenal / ovarial / testicular dysfunction, local fat deposits, adiposis, bilirubin metabolism disturbances, mucoviscidosis.About the Author:Read about hair loss treatment, hair loss cure. Read about bodybuilding tips, bodybuilding supplements, bodybuilding guide and acne cure, acne treatment, acne solutionIt is not very hard to avoid acute Bronchitis . It is necessary just to wash your hands frequently, get more rest and drink plenty of liquids. Acute bronchitis is usually caused by viruses or bacteria. One can be contaminated with this agents by breathing coughing droplets from the air or by touching contaminated surfaces, by breathing polluted, by smoking or breathing cigarette smoke or other harmful smokes.UROGENITAL SYSTEM DISEASES: Glomerulonephritis, acute and chronic nephritic syndrome, acute and chronic tubulointerstitial nephritis, acute and chronic pyelonephritis, reflux-uropathy, toxic nephropathy, hydronephrosis (without obstruction), urolithiasis, renal ischemia or infarction, acquired renal cyst, acute and chronic cystitis, neuromuscular dysfunction of the urinary bladder, urethritis, urinary tract infection without definite localization, enuresis; hyperplasia of the prostate, adenoma of the prostate, acute and chronic prostatitis, prostatocystitis, prostatic calculus, orchi-tis and epididimitis, balanopostitis, vascular disorders of male genital organs, certain forms of male sterility; mastopathia fibrocystica, mastitis, lactostasis, nipple cracks and fistulae; salpingitis and oophoritis, vulvovaginitis, incomplete vaginal prolapse, ovarial cysts, incorrectwomb positions, cervical erosion, myoma and fibromyoma, absence of menstruations, poor and rare menstruations, frequent, irregular menstruations, premenstrual syndrome, menstrual pains, early menopause, climacteric status, recurrent abortion, secondary female sterility.

Read More…

To find out more regarding various kinds of headaches and how to treat them, consisting of the latest Botox treatment alternative, join us at our totally free seminar!

Register Online (Limited Seating):

COMPLIMENTARY Migraine Relief Seminar offered by Dr. Eddie Patton Jr., Tuesday, May 21 at 6 p.m

. There will certainly be refreshments and door rewards for participants. – Kim

1 2 3 73